Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease
British Journal of Clinical Pharmacology2019Vol. 85(5), pp. 935–948
Citations Over TimeTop 10% of 2019 papers
Matthew J. Sheetz, Philip Barrington, Sophie Callies, Paul H. Berg, Juliet McColm, Thomas Marbury, Brian S. Decker, Gregory L. Dyas, Stephanie M.E. Truhlar, Robert J. Benschop, Donmienne Leung, Jolene Kay Berg, Derrick R. Witcher
Abstract
LY3113593 and LY2928057 pharmacological effects (serum iron and ferritin) were translated from preclinical-to-clinical development. Such interventions may lead to new CKD anaemia treatments.
Related Papers
- → Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization(2004)4,725 cited
- → Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor(2014)23 cited
- → Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease(2020)15 cited
- → Is hepcidin an iron cluster peptide?(2004)3 cited
- → Copper deficiency increases ferroportin expression in rats(2009)